Alzheimer"s Imaging Biomarkers in Obesity

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Cyrus A Raji
Study ID
NCT05077579
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 60 Years
Healthy Volunteers
Accepted

Study Details

High body fat at midlife, as evidenced by overweight or obese body mass index (BMI), is increasingly understood as a risk factor for Alzheimer's disease. However, the underlying processes and mechanisms that may underlie this risk remains unknown. With this project, the Investigator proposes to create a new cohort of cognitively normal 120 midlife individuals, age 40-60 years. The investigator and research staff will characterize the participant's overweight or obese status using metabolic tests including, an oral glucose tolerance test, fasting plasma insulin, fasting plasma glucose, and hemoglobin A1c measurements. This testing will generate categories of metabolically abnormal overweight and obese (MAOO), metabolically normal overweight and obese (MNOO), and metabolically normal lean participants (MNLP). Research staff will evaluate differences between these groups on neuroimaging with the newer classification framework of Alzheimer's biomarkers with amyloid (A), tau (T), and neurodegeneration (N), or ATN. Neurodegeneration will be assessed by atrophy on brain MRI as reflected by regional volumes on Freesurfer. Staff will also evaluate MR neuroimaging markers for neuroinflammation using a newer method called diffusion basis spectrum imaging (DBSI), developed at the Mallinckrodt Institute of Radiology at Washington University in St. Louis in collaboration with The Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight ADRC).

Key Dates

Start date
Oct 18, 2021
Status verified
May 2026
Primary completion
May 1, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
240 participants (estimated)

Arms

  • Arm: metabolically abnormal overweight & obese
  • Arm: metabolically normal overweight
  • Arm: obese and metabolically normal lean

Primary Outcome Measure

Aim - increased atrophy in MAOO compared to MNOO and MNLP participants [ Time Frame: 10 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
LaKisha A Lloyd, MS
[email protected]
3143627315
Nancy A Hantler, BS
[email protected]
3143627315

Find similar trials in St Louis, MO

By condition
Alzheimer's diseaseObesity / overweight
By specialty
NeurologyDementia careBrain disordersGeriatricsEndocrinologyMetabolic healthWeight loss
By research site
Washington University School of Medicine· St Louis, MO

Related Studies